Corporate Overview | July 2022 3 Corporate Overview | July 2022 4

Thursday, July 21, 2022 BiopharmaWatch Research 1 min read

Key Takeaway: Corporate Overview | July 2022 3 Corporate Overview | July 2022 4

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice

Cash runway

~61 mo

Minimal dilution risk

Lead asset

DT120

Phase 3 · Major Depressive Disorder

Corporate Overview | July 2022 3 Corporate Overview | July 2022 4